Search clinical trials for: Beta Carotene

Total 6067 results

Ain Shams University

Recruiting

Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Copd

Copd

Egypt
National Taiwan University Hospital

Completed

Predictors for Retreatement of OAB After DC Mirabegron

Recurrence of Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Jagiellonian University
University Hospital in Krakow

Not yet recruiting

Beta-blockade in Unruptured Intracranial Aneurysm (BBLURAN)

Intracranial Aneurysm

Poland
Meshalkin Research Institute of Pathology of Circulation

Recruiting

Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy

Hypertrophic Obstructive Cardiomyopathy

Russian Federation
Philip Kern
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Mechanisms for Activation of Beige Adipose Tissue in Humans

PreDiabetes

United States
Astellas Pharma China, Inc.

Completed

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

Urge Incontinence | Overactive Bladder (OAB)

China
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Global Development, Inc.

Completed

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB) (PILLAR)

Overactive Bladder (OAB)

United States, Canada
Philadelphia Urosurgical Associates
Astellas Pharma Global Development, Inc.

Terminated

A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis (MirabegronIC)

Cystitis, Interstitial

United States
Astellas Pharma Inc

Completed

A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (ARIES)

Urinary Bladder, Overactive

United States, Canada
Astellas Pharma Inc

Completed

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (CAPRICORN)

Urinary Bladder, Overactive

United States, Hungary, Canada, Spain, Finland, Slovakia, Czechia, Sweden, Germany, Denmark, Norway
Massachusetts General Hospital
Forest Laboratories

Completed

Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease (NIRVANA)

Microvascular Angina

United States
Saint Francis Care
Biogen

Completed

Assessing Tolerability of Avonex Intramuscular Injections

Multiple Sclerosis

United States
Central Hospital, Nancy, France
Baxter Healthcare Corporation

Unknown

Esmolol Effects on Heart and Inflammation in Septic Shock (ESMOSEPSIS)

Septic Shock

France
Rempex Pharmaceuticals (a wholly owned subsidiary...

Completed

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects

Bacterial Infections | Healthy Volunteers

Australia
Astellas Pharma Inc

Completed

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Lower Urinary Tract Symptoms | Bladder Outlet Obstruction

United States, Canada
Astellas Pharma Inc

Completed

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Renal Impairment

United States
Qilu Hospital of Shandong University

Enrolling by invitation

A Randomized Controlled Study on the Treatment of Cirrhosis Combined With Hypersplenism

Liver Cirrhosis | Esophageal and Gastric Varices | Hypersplenism

China
Aaron Boster
Pfizer; EMD Serono

Completed

Combination Therapy Using Cellcept and Rebif in RRMS

Multiple Sclerosis

United States
Rempex (a wholly owned subsidiary of Melinta Therapeutics...
Department of Health and Human Services

Recruiting

Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections (TANGOKIDS)

Bacterial Infections

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Relapsing Remitting Multiple Sclerosis
The University of Hong Kong

Unknown

IFN-beta 1b and Remdesivir for COVID19

Covid19

Hong Kong
Samsung Medical Center

Completed

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

Overactive Bladder

Korea, Republic of
Jack Rubinstein
Forest Laboratories

Terminated

An Advanced Echocardiographic Evaluation of Nebivolol

Hypertension

United States
Mylan Bertek Pharmaceuticals

Completed

Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension

Hypertension

United States
Shahid Beheshti University of Medical Sciences

Unknown

the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19

Covid19
Mylan Bertek Pharmaceuticals

Completed

A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo

Hypertension

United States
Henry M. Jackson Foundation for the Advancement...
Johns Hopkins University

Recruiting

Virtual Reality to Enhance Upper Extremity Physical Therapy and Recovery

Injuries to the Hand and Wrist

United States
Zhongshan Ophthalmic Center, Sun Yat-sen University

Not yet recruiting

Multimodal Equipment for Teleophthalmology Assessment (META)

Eye Diseases
Genentech, Inc.

Completed

A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease

Alzheimer's Disease
Fred Hutchinson Cancer Center
ImmunoGen, Inc.

Recruiting

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Myelodysplastic/Myeloproliferative Neoplasm | Mixed Phenotype Acute Leukemia

United States
University of Sao Paulo

Recruiting

The Influence of Exercise on Tissue Beta-alanine Uptake and Carnosine Synthesis Rates

Exercise Training | Dietary Supplements | Carnosine

Brazil
Nottingham Trent University
Aston University

Completed

β-alanine Supplementation in Adults With Overweight/Obesity (BASA-O)

Hyperglycemia | Overweight or Obesity | Prediabetes

United Kingdom
Steno Diabetes Center Copenhagen

Completed

Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19 (KetoCOVID)

COVID-19

Denmark
Atlas Biomed

Withdrawn

Dietary Fibers Effect on the Gut Microbiota Composition

Inflammation | Metabolic Syndrome | Dyslipidemias | Cardiovascular Risk Factor | Microbiome

Russian Federation
Hoffmann-La Roche

Completed

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Anemia

United States, Canada, United Kingdom, Mexico, Poland
Hoffmann-La Roche

Completed

A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia

Anemia

Egypt
Hoffmann-La Roche

Completed

An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)

Kidney Disease, Chronic

Slovenia
University Hospitals Bristol and Weston NHS Foundation...

Completed

Towards Simple and Non-invasive Assessment of Residual Beta-cell Function in Type 1 Diabetes

Type 1 Diabetes

United Kingdom
Nuron Biotech Inc.

Unknown

Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing Remitting Multiple Sclerosis

Poland, Spain, Belarus, Bulgaria, Serbia, Ukraine, Russian Federation, Hungary, Italy, Croatia, Georgia, Lebanon
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Predialysis Patients

Anemia in Pre-Dialysis Patients

Japan
Astellas Pharma Europe B.V.

Completed

Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (Crocodile)

Neurogenic Detrusor Overactivity

Belgium, Croatia, Turkey, Australia, Denmark, Israel, Jordan, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Norway, Philippines, Poland, Romania, Serbia, Slovakia, Taiwan
Minneapolis Heart Institute Foundation
Forest Laboratories

Terminated

Alternative in Beta Blocker Intolerance: The ABBI Trial (ABBI)

Coronary Artery Disease

United States
Velicept Therapeutics, Inc.

Completed

Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects

Healthy Subjects, Overactive Bladder
Merck KGaA, Darmstadt, Germany

Completed

Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis

Multiple Sclerosis

Korea, Republic of
Astellas Pharma Inc

Completed

To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

Healthy Subjects | Pharmacokinetics

Netherlands
Daniel Burdick, MD
Astellas Pharma US, Inc.

Completed

A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO) (Maestro)

Parkinsons Disease

United States
Ain Shams University

Unknown

Role of Intraoperative Beta Blocker for Morbid Obese Patients Undergoing Laparoscopic Bariatric Surgery

Postoperative Pain | Intraoperative Awareness

Egypt
HealthPartners Institute

Completed

Mirabegron in Parkinson Disease and Impaired Cognition (MICT-PD)

Overactive Bladder | Parkinson Disease | Impaired Cognition

United States

Search clinical trials for: Beta Carotene

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations